Results 71 to 80 of about 924 (199)

Combate à resistência aos antibióticos : novas moléculas/estratégias em fase clínica de desenvolvimento [PDF]

, 2023
Dissertação para obtenção do grau de Mestre no Instituto Universitário Egas MonizIntrodução: A resistência antimicrobiana é a capacidade de um microrganismo impedir que um agente antimicrobiano funcione contra ele, impondo sérias limitações no tratamento
Nunes, Pedro Miguel Ascensão
core  

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies

Clinical Infectious Diseases, 2023
AbstractSulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. Durlobactam is a member of the diazabicyclooctane class of β-lactamase inhibitors with broad-spectrum serine β-lactamase activity.
Papp-Wallace, Krisztina M, McLeod, Sarah M, Miller, Alita A   +2 more
openaire   +2 more sources

Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates

ChemMedChem, Volume 19, Issue 21, November 4, 2024.
We report the synthesis and evaluation of molecular conjugates that combine a carbapenem antibiotic (meropenem or ertapenem) with a recently reported indole carboxylate scaffold. These hybrids are potent inhibitors of metallo‐β‐lactamases including the clinically relevant NDM‐1 and IMP‐1 enzymes.
Mei‐Ling Gao, Ioli Kotsogianni, Foteini Skoulikopoulou, Nora C. Brüchle, Paolo Innocenti, Nathaniel I. Martin   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source

Burden and Management of Multi-Drug Resistant Organism Infections in Solid Organ Transplant Recipients Across the World: A Narrative Review [PDF]

Solid organ transplant (SOT) recipients are particularly susceptible to infections caused by multidrug-resistant organisms (MDRO) and are often the first to be affected by an emerging resistant pathogen.
Freire M. P., Giannella M., Manesh A., Pouch S.   +3 more
core   +1 more source

Nuevos inhibidores de β-lactamasas frente a patógenos gram negativos multirresistentes [PDF]

, 2022
Programa Oficial de Doutoramento en Ciencias da Saúde. 5007V01[Resumo] As especies Acinetobacter baumannii, Pseudomonas aeruginosa e a orde Enterobacterales son categorizados como patóxenos de prioridade crítica para o desenvolvemento de novos ...
Vázquez-Ucha, Juan Carlos
core  

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Microorganisms
Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because
Noayna Arshad, Wael Azzam, Marya D. Zilberberg, Andrew F. Shorr   +3 more
doaj   +1 more source

Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data

Antimicrobial Agents and Chemotherapy
ABSTRACT Sulbactam–durlobactam is a β-lactam/β-lactamase inhibitor combination approved in the United States for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus in adults.
Anthony P. Cammarata, M. Courtney Safir, Michael Trang, Kajal B. Larson, John P. O'Donnell, Sujata M. Bhavnani, Christopher M. Rubino   +6 more
openaire   +2 more sources

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +1 more source